KCI in stealthy buyout of MoMelan | Wall Street Beat

Kinetic Concepts executed an under-the-radar buyout of skin graft developer MoMelan Technologies, according to Xconomy.com, citing an anonymous investor in MoMelan.

The acquisition, to which the investor declined to assign a value, is "a good outcome for everybody – founders, investors, employees,” according to the unnamed source.

KCI asked MoMelan to keep the deal under wraps, according to Xconomy.

The MoMelan technology, for which the company reeled in $5 million last year, involves a device that expands the surface area of skin grafts for treatment of skin disorders.

NxStage board member pares stake
David Utterberg,
a board member at NxStage Medical (NSDQ:NXTM) and chairman of Lifestream Medical, cut nearly 10% from his stake in the home hemodialysis company, according to a regulatory filing.

Utterberg now owns some 4.5 million NXTM shares, for about a 7.6% share, according to the filing.
Read more

Palomar OKs 1.5M share buyback
Palomar Medical (NSDQ:PMTI) said its board approved a stock repurchasing program for 1.5 million shares of its own stock, effective immediately. PMTI shares were trading at $8.18 as of about 1 p.m. today.
Read more

Baxter logs yet another 52-week high

Shares of Baxter (NYSE:BAX) hit another in a series of 52-week highs, reaching $66.88 apiece Nov. 14.

Medisafe 1 inks $7M licensing deal
Medisafe 1 Technologies (OTC:MFTH) said it signed a $7 million non-exclusive perpetual license for the full commercialization, marketing and distribution of its patented medicinal locking mechanism and bar-code matching system to SafeCode Drug Technologies Corp.
Read more

Analysts’ ups and downs

Bruker Corp. (NSDQ:BRKR): Goldman Sachs upgrades from "neutral" to "buy" rating, raises price target from $13 to $19.
Intuitive Surgical (NSDQ:ISRG): SunTrust initiates coverage with “buy” rating, $598 price target.
Sirona Dental Systems (NSDQ:SIRO): Jefferies & Co. reiterates "buy" rating, raises price target from $57 to $71.
Stryker (NYSE:SYK): Zacks maintains "neutral" rating, $55 price target.